Substrate Specificity of T7 RNA Polymerase toward Hypophosphoric Analogues of ATP

Modified nucleotides are commonly used in molecular biology as substrates or inhibitors for several enzymes but also as tools for the synthesis of modified DNA and RNA fragments. Introduction of modification into RNA, such as phosphorothioate (PS), has been demonstrated to provide higher stability, more effective transport, and enhanced activity of potential therapeutic molecules. Hence, in order to achieve widespread use of RNA molecules in medicine, it is crucial to continuously refine the techniques that enable the effective introduction of modifications into RNA strands. Numerous analogues of nucleotides have been tested for their substrate activity with the T7 RNA polymerase and therefore in the context of their utility for use in in vitro transcription. In the present studies, the substrate preferences of the T7 RNA polymerase toward β,γ-hypophospho-modified ATP derivatives for the synthesis of unmodified RNA and phosphorothioate RNA (PS) are presented. The performed studies revealed the stereoselectivity of this enzyme for α-thio-β,γ-hypo-ATP derivatives, similar to that for α-thio-ATP. Additionally, it is demonstrated herein that hypodiphosphoric acid may inhibit in vitro transcription catalyzed by T7 RNA polymerase.


INTRODUCTION
Modified nucleosides and nucleotides make up a class of compounds with a wide range of therapeutical applications and utilities in molecular biology.These natural counterparts are known as signaling molecules, agonists of receptors, substrates and cofactors of enzymes, as well as the building blocks for RNA synthesis. 1,2Through the multifunctional nature of nucleosides and nucleotides, their analogues are commonly designed and synthesized for the regulation of signaling pathways acting as substrates, inhibitors, cofactors of enzymes, or agonists or antagonists of receptors. 3One of the most important applications of modified nucleotides is also their use as building blocks for the synthesis of DNA and RNA. 4,5This role of modified nucleotides has recently become particularly important, especially with the widespread utilization of mRNA vaccines to combat the spread of SARS-CoV-2. 6−8 Nowadays, mRNA-based drugs are considered to open a new era of therapeutic approaches. 9Introduction of modifications into RNA has been commonly used for years to provide higher stability and more effective transport and to enhance the activity of such modified molecules. 5,10 common way to introduce modifications into the RNA strand is in vitro RNA transcription.Several bacteriophage enzymes such as T7, T3, and Sp6 RNA polymerases have been shown to catalyze the in vitro synthesis of modified RNA molecules.5,11 The T7 RNA polymerase, as one of the most common enzymes involved in RNA production, is particularly interesting due to its wide substrate tolerance.
The PS modification has been shown to enhance stability 30 and improve translation of such modified mRNA, allowing more efficient synthesis of proteins. 31The T7 RNA polymerase is known to recognize 5′-triphosphates of α-thio-nucleosides in a stereocontrolled manner. 23,32,33Only the S P diastereoisomer of adenosine 5′-O-(1-thiotriphosphate) was shown to be incorporated into the RNA strand, whereas the R P diastereoisomer was neither a substrate nor a competitive inhibitor of the enzyme. 23A similar effect was observed in the synthesis of phosphoroselenoate, where also only the S P isomer of adenosine 5′-(α-P-seleno)triphosphate was used as a substrate by T7 RNA polymerase. 25P-stereoselectivity was also demonstrated toward diastereomers of 5′-(α-P-borano)triphosphates. 33vestigation of compounds that can interact with T7 RNA polymerase is important, not only in the context of their substrate activity and potential utility for incorporation of modifications into RNA strands via in vitro transcription but also in terms of their potential inhibitory activity.Based on some structural similarities in RNA polymerases, the data obtained for T7 RNA polymerase may also be useful for the rational design of antiviral agents. 34

Preparation of the Experimental Model for
In Vitro Transcription Studies.The aim of this study was to verify the utility of α-thio-β,γ-hypo-ATP (4) derivatives for the synthesis of phosphorothioate (PS)-modified RNA molecules via the in vitro transcription method using T7 RNA polymerase.For the comparison of sulfur incorporation efficiency and for enzyme preferences toward individual diastereomers, both β,γ-hypo-ATP (3) and α-thio-ATP (2) derivatives were also synthesized and analyzed as substrates for T7 RNA polymerase (Figure 1).All analogues were obtained via the oxathiaphospholane method and separated into individual diastereomers, as described previously 1,35 using a two-step purification protocol.After initial purification on Sephadex resin, α-thio−modified ATP analogues were separated into individual P-diastereomers, i.e., fast and slow according to their relative chromatographic mobility, using revered-phase high-performance liquid chromatography (RP- HPLC; for details, see M&M section).After the separation, the purity of the products was verified by analytical HPLC and confirmed by NMR spectroscopy and high-resolution mass spectrometry (see the Supporting Information).The absolute configuration at the P-stereogenic center in the synthesized αthio-modified ATP analogues was assigned based on 1 H NMR spectroscopy and the relative mobility during RP-HPLC analysis.The first indication of a possible stereoconfiguration of compounds was chromatographic mobility.Previous data had indicated that diastereomers with an S P configuration have often a shorter retention time during RP-HPLC separation than their R P counterparts. 36,37The NMR analysis was based on previous studies, where it was demonstrated that in the case of β,γ-modified α-thio-ATP derivatives, the H8 signal should be more shielded in the S P isomer than in the isomer R P as a result of the influence of the negatively charged α phosphorus moiety. 38,39Our observations also indicated that fast-eluting compounds 2 and 4 have an S P configuration, whereas sloweluting ones have an R P configuration (8.48 vs 8.42 and 8.56 vs 8.49 for isomers fast and slow of compounds 2 and 4, respectively).Besides the NMR and RP-HPLC migration rate results, the stereoconfiguration of α-thio-ATP (2) derivatives was also confirmed by coinjection with commercially available S P and R P diastereomers.
To test the substrate activity of the modified ATP analogues the in vitro transcription experiments were performed following a previously described model. 40In the first step, in order to obtain the double-stranded, dsDNA matrix fragment, the DNA template and appropriate primers were used for DNA amplification.Then, based on the obtained dsDNA fragment, the complementary RNA strand was synthesized through the in vitro RNA transcription catalyzed by T7 RNA polymerase (Figure 1).The products of the reaction were analyzed via polyacrylamide gel electrophoresis (PAGE), ultraperformance liquid chromatography coupled with mass spectrometry (UPLC-ESI(−)-MS), and a microfluidic analyzer.

In Vitro
Transcription with Hypo-Modified ATP Analogues as Substrates for T7 RNA Polymerase.The diastereomerically pure α-thio-β,γ-hypo-ATP (S P -4 and R P -4) analogues were analyzed for their substrate activity with the T7 RNA polymerase.The 120 nt length RNA products were synthesized based on the 140nt dsDNA matrix in the in vitro transcription reaction.The RNA molecules were separated and detected by polyacrylamide gel electrophoresis and using the Agilent 2100 Bioanalyzer (Agilent).Both PAGE and bioanalysis results indicated that only the S P diastereomer of α-thio-β,γ-hypo-ATP (S P -4) may be a substrate for T7 RNA polymerase, whereas the use of its R P counterpart did not lead to obtaining the RNA product (Figure 2).
The stereoselectivity of T7 RNA polymerase for S P diastereomers of α-thio-ATP and other α-modified nucleoside triphosphates has been reported previously. 23,32,33The results obtained herein indicated that the T7 RNA polymerase exhibits stereoselective activity not only for α-thiobut also for the α-thio-β,γ-hypo-modified substrates.
In order to confirm whether the S P diastereomer of α-thioβ,γ-hypo-ATP (S P -4) actually acts as a substrate for T7 RNA polymerase, and whether the RNA product of synthesis contains the phosphothioate modification, the product of in vitro transcription was purified and analyzed using mass spectrometry.For the comparison with (S P )-α-thio-β,γ-hypo-ATP, a control reaction was also performed using (S P )-α-thio-ATP (S P -2) and ATP (1) as known substrates for this enzyme, where the expected products were phosphorothioate RNA (PS-RNA) for S P -2 and an unmodified RNA strand for 1, respectively.Mass spectrometry analysis has proven the introduction of phosphorothioate modification into the newly synthesized RNA strand during the in vitro transcription process when the (S P )-α-thio-β,γ-hypo-ATP (S P -4) molecule was used as a substrate for the in vitro synthesis catalyzed by T7 RNA polymerase (Figure 3).
The results obtained for α-thio-β,γ-hypo-ATP (4) are in accordance with numerous literature data indicating selectivity toward the S P diastereomer of α-thio-modified ATP derivatives. 23,32,33Based on these results, we propose the analysis of T7 RNA polymerase activity as an indirect method for the determination of the stereochemical configuration of α-thiomodified nucleotides containing additional modifications such as β,γ-substitution.
Besides T7 RNA polymerase stereoselectivity, the differences in the reaction yield when using β,γ-hypophosphomodified ATP analogues compared to natural substrates were detected.The decrease of in vitro efficacy was observed not only when using (S P )-α-thio-β,γ-hypo-ATP (4), where the PS-RNA was produced, but also for β,γ-hypo-ATP (3), where the expected product was unmodified RNA (Figure 4).This observation suggests potential differences in the substrate preferences of T7 RNA polymerase toward β,γ-hypo-modified ATP derivatives compared to unmodified counterparts or the inhibitory activity of hypodiphosphate produced during RNA synthesis from these derivatives.The mass spectrometry analysis indicated that S P -4 could serve as a substrate for the synthesis of PS-modified RNA (Figures 2 and 3), if unmodified ATP was present in the mixture, the main product of in vitro transcription catalyzed by T7 RNA polymerase was the unmodified RNA.The RNA containing the phosphorothioate modification was present; however, the fully modified RNA was not produced or was produced at yields below the detection threshold when the mix S P -α-thio-β,γ,-hypo-ATP/ATP was used for the reaction (Figure 5 left).Interestingly, using S P -α-thio-ATP under the same conditions resulted in obtaining expected PS-modified products (Figure 5 right).This disproportion suggested the different affinity of α-thio-ATP (2) and α-thio-β,γ-hypo-ATP (4) toward T7 RNA polymerase, the different specificity of interaction with the substrates, or the inhibitory activity of one of the products formed during the reaction.Mass spectra of the [M-9H + ] 9− ion of the reaction products in the presence of the mixture 1/S P -2 and 1/S P -4, as well as simulated mass spectra of unmodified and PS-modified products, are given in the Supporting Information (Figure S22).

Efficacy of RNA Synthesis by T7 RNA Polymerase in the Presence of α-Thio-β,γ-hypophospho-Modified
ATP Derivatives.In order to verify whether the presence of α-thio-β,γ-hypo-ATP (4) derivatives may affect the T7 RNA polymerase activity, an in vitro transcription was performed using all canonical nucleoside triphosphates (GTP, CTP, UTP, and ATP) and increasing quantities of S P or R P diastereomers of α-thio-β,γ-hypo-ATP (4), respectively.Tested ATP analogues were used at concentrations 0.1, 0.5, 1, and 2 mM, with 0.5 mM concentration of the remaining nucleotide triphosphates (NTPs), which leads to the following ratio of ATP analogue to ATP: 0.2:1, 1:1, 2:1, and 4:1.The obtained results clearly showed a reduced yield of the RNA product when using S P -α-thio-β,γ-hypo-ATP (S P -4), which was demonstrated to be a substrate for T7 RNA polymerase compared to its unreacted R P counterpart (R P -4) (Figure 6). the PAGE analysis of the in vitro transcription demonstrated that an increased amount of S P -α-thio-β,γ-hypo-ATP (S P -4) derivatives resulted in no detection of the reaction product despite the presence of necessary nucleotides (GTP, CTP, UTP, and ATP), which was not observed for the R P diastereomer (R P -4).One of the possible explanations for this phenomenon could be the partial inhibitory activity of the S P derivative.Another possibility is that at high concentrations of the S P -4 diastereomer, when a larger amount of substrate is used, leading to an increased amount of the reaction product,  the activity of the enzyme may inhibited.This corroborates with the fact that such a strong inhibition was not observed for the R P diastereomer of 4, which was not a substrate and therefore did not lead to the formation of the hypodiphosphate.
2.5.In Vitro Transcription in the Presence of Pyroand Hypodiphosphoric Acid.One of the most probable explanations for the decreased efficacy of the in vitro transcription reaction in the presence of S P -4 seemed to be the inhibitory activity of hypodiphosphoric acid, which is the product of the T7 RNA polymerase reaction, when β,γ-hypomodified derivatives were used as effective substrates.In order to verify this hypothesis, in vitro transcription was performed in the presence of hypodiphosphoric acid and pyrophosphoric acid using unmodified NTP substrates, separately (Figure 7).Indeed, the electrophoretic analysis of the in vitro transcription mixture showed the inhibition of the reaction catalyzed by the T7 RNA polymerase in the presence of hypodiphosphoric acid, whereas at the same concentration, the reaction was not affected by pyrophosphoric acid (Figure 7).This result clearly confirmed the inhibitory activity of hypodiphosphoric acid for T7 RNA polymerase.Whereas a slight decrease of the in vitro transcription activity with a higher concentration of pyrophosphoric acid has been previously reported, and this was observed in our studies (Figure S23), the inhibitory activity of hypodiphosphoric acid toward T7 RNA polymerase has never been demonstrated.Hypodiphosphoric acid has been considered to interact with placental alkaline phosphatase (PLAP) 41 and tissue-nonspecific alkaline phosphatase (TNAP) 42 and was demonstrated to be a substrate of pyrophosphorolysis catalyzed by HIV-1 reverse transcriptase; 43 however, to date, little is known about the other biological properties of this molecule. 44Thus, the obtained results make a significant contribution toward the knowledge about this molecule and the potential activity of its derivatives.

CONCLUSIONS
We have demonstrated here, for the first time, the substrate preferences of T7 RNA polymerase for selected β,γ-hypomodified ATP analogues, thus indicating their potential utility in the in vitro synthesis of both unmodified RNA and phosphorothioate RNA.Despite the unquestionable advantages provided by phosphorothioate modification, the determination of the absolute stereoconfiguration of such modified nucleotides meets some difficulties.The T7 RNA polymerase is one of the enzymes known to stereoselectively recognize the S P diastereomer of α-thio-ATP.Herein, we have indicated that stereoselectivity of the enzyme may be applicable to α-thiomodified nucleotide derivatives with β,γ-modification, which makes it a potential tool for assignment of absolute configuration of not only α-thiobut also α-thio-β,γ-modified nucleotides.
Additionally, for the first time, hypophosphoric acid was demonstrated to decrease the efficiency of the in vitro transcription catalyzed by T7 RNA polymerase.Our observation opened a new way for studying the mechanistic properties of T7 RNA polymerase action, its substrate activity toward various β,γ-modified nucleotides, and possible inhibition by bisphosphonates formed as reaction products.This type of mechanistic study may lead to the understanding of efficient and effective synthesis of modified RNAs and is particularly valuable in terms of optimizing the production and introducing further RNA-based therapeutics to the market.Moreover, the model in which the inhibitory effect on T7 RNA polymerase is caused by the product of its action is interesting in the context of potential inhibition of viral RNA polymerases and the rational design of antiviral drugs.

Synthesis of ATP Analogues. The adenosine 5′-O-
(1-thiotriphosphate) analogues, presented in this paper, were synthesized via the oxathiaphospholane method 45,46 according to the procedure described previously. 1 The protected adenosine 5′-O-(2-thio-1,3,2-oxathiaphospholane) in the presence of DBU as a base catalyst was reacted with pyrophosphate or hypophosphate for compounds 2 and 4, respectively.The ring-opening reaction followed by the spontaneous elimination of ethylene sulfide led to the desired analogues.The reactions were performed at room temperature with the exclusion of moisture.After the deprotection step, with 25% aqueous ammonia, the compounds were purified by ion-exchange chromatography (DEAE-Sephadex) using triethylammonium bicarbonate (TEAB) as an eluent.The β,γ-hypo-ATP (3) was obtained from the starting α-thio-β,γ-hypo-ATP (4) (as a diastereomeric mixture) using iodoxybenzene according to a previously published protocol. 1The obtained compounds were additionally purified and separated into the individual Pdiastereoisomers using high-performance liquid chromatography (RP-HPLC) with linear gradient 0−30% MeCN  with 0.1 mol/L triethylammonium acetate buffer (TEAAc) (pH 7.5).The final quality of the compounds was achieved by analytical RP-HPLC analysis.

Preparation of dsDNA Template.
The DNA template, used for transcription studies, was prepared by amplification using a polymerase chain reaction (PCR).For PCR, the DNA template strand (DNA.tmp) with the DNA forward strand (DNA.fwd) and the DNA reverse strand (DNA.rev), with the sequence presented in Figure 1, was used.Each PCR was carried out in 100 μL volume, and the reaction mix consisted of 0.004 μM DNA template, 1 μM primer forward, 1 μM primer reverse, and 1× PCR master mix (PCR Plus mixture solution from A&A Biotechnology).Both primer strands and the DNA template strand were purchased from Genomed.Concentrations of all oligonucleotides were estimated using a NanoDrop spectrophotometer (Thermo-Scientific).

4.3.
In Vitro Transcription.The T7 RNA in vitro transcription was performed based on the procedures described previously. 40,47The transcription reaction was carried out in a 50 μL final volume by combining equimolar amounts of three nucleoside triphosphates, 0.5 mM GTP, UTP, and CTP, and selected ATP analogues.For the positive control, 0.5 mM GTP, UTP, CTP, and ATP were used.The negative control was prepared without ATP or ATP analogues.For the assessment of reaction efficiency, the ATP or ATP derivative was used at concentrations of 0.1, 0.5, 1, and 2 mM.The in vitro transcription was performed in the presence of 25 mM MgCl 2 , 40 mM Tris-HCl, 10 mM dithiothreitol, and 2 mM spermidine, at pH = 7.9 with 1 U/μL T7 RNA polymerase (Lucigen).The reaction was carried out at 37 °C for 4 h and stopped by addition of 25 μL of a 7 M urea−40 mM EDTA buffer and heating to 90 °C for 3 min.
4.4.T7 RNA Polymerase Efficiency in the Presence of Tested Compounds.The enzymatic mix was prepared in a 50 μL final volume by combining equimolar amounts of four nucleoside triphosphates, 0.5 mM GTP, UTP, CTP, and ATP, and a variable concentration of tested compounds.In cases of hypo-and pyrophosphate impact studies, the reaction was performed in the presence of 0.5 mM hypodiphosphoric acid or pyrophosphoric acid, respectively, with an increasing concentration of ATP.Selected ATP analogues or ATP was titrated to the final concentrations of 0.1, 0.5, 1, and 2 mM.Transcription was carried out in the presence of 25 mM MgCl 2 , 40 mM Tris-HCl, 10 mM dithiothreitol, and 2 mM spermidine, at pH = 7.9 and 1 U/μL T7 RNA polymerase (Lucigen).The transcription reaction was carried out at 37 °C for 4 h and stopped by the addition of 25 μL of a 7 M urea−40 mM EDTA buffer and heating to 90 °C for 3 min.
4.5.Polyacrylamide Gel Electrophoresis Analysis.The reaction mixtures were analyzed with a 10% denaturing polyacrylamide gel.Electrophoresis was performed using 10% acrylamide:bis-acrylamide gel (19:1) in 7 M urea, 50 mM TRIS, 50 mM boric acid, and 1 mM EDTA.The electrophoresis was run for 3 h at 300 V at room temperature.The RNA products were visualized using a Stains-all solution (Stains-all 50 μg/mL (Sigma-Aldrich), 10% formamide, 25% isopropanol, 50 mM TRIS, 50 mM boric acid).After overnight staining, the PAGE gels were washed three times with Milli-Q water.Gel images were analyzed densitometrically by using ImageJ software.Results were normalized to an internal positive control with ATP, which was taken as 100%.The remaining results were estimated in relation to this value.4.6.Bioanalysis.Bioanalysis of T7 RNA polymerase reaction products was performed using the Agilent 2100 Bioanalyzer (Agilent).For analysis, "RNA nano chip" (Agilent) and the "Eukaryote total RNA Nano II" bioanalysis program were used.Analysis was performed using 1 μL from each transcription sample.Procedures were performed in accordance with the manufacturer's recommendations.4.7.Preparation of Samples for Mass Spectrometry Analysis.For the mass spectrometry analysis, the in vitro transcription reaction was scaled up 4-fold from the 50 to 200 μL final volume.Master mix was prepared by mixing 0.5 mM UTP, GTP, and CTP with 19 mM MgCl 2 and T7 polymerase buffer, DNA template, and T7 polymerase.Each sample contains 25 mM Mg 2+ from the buffer and MgCl 2 solution.RNA-ase free water was added first to 500 μL tubes, and then, appropriate amounts of ATP or ATP analogues were added and supplemented with the master mix.Short, synthetic 10nt dsDNA was used as a template.
Transcription was performed for 4 h at 37 °C in 200 μL volume.After transcription, samples were mixed with 100 μL of urea/EDTA and incubated at 90 °C for 3 min.Then, samples were applied on the 10% PAGE gel and 7 M urea (20 mL of 20% acrylamide:bis-acrylamide 19:1, 7 M urea, 16 mL of 7 M urea, 4 mL of 10x TBE).The gel was run at 300 V for 2 h.Then, RNA samples were extracted from the gel.
For this purpose, RNA bands were cut out from the gel and placed in Eppendorf tubes with 600 μL of elution buffer.Gel samples were incubated overnight at 8 °C with constant mixing at 350 rpm.A solution of the eluent from overnight incubation was separated from the acrylamide gel pieces and gently mixed with 100% ice-cold ethanol and incubated in a freezer (−20 °C) for a minimum of 2 h.After that, the samples were washed.For this purpose, tubes were centrifuged for 20 min, 12,000 rpm at 4 °C, and the liquid was removed.Then, 70% ethanol was added to the pellet and samples were centrifuged again for 10 min, 12,000 rpm at 4 °C.After removing of the supernatant, purified RNA was dried in the Speedvac and resuspended in RNase and DNase free water.The concentration of RNA was measured using Nanodrop.Finally, samples were dried using a Speedvac centrifuge, and mass spectrometry analysis was performed.
4.8.Mass Spectrometry.All samples were analyzed using an ACQUITY UPLC I-Class chromatography system equipped with a photodiode array detector with a binary solvent manager (Waters Corp., Milford, MA) coupled with a SYNAPT G2-Si mass spectrometer equipped with an electrospray source and a quadrupole time-of-flight mass analyzer (Waters Corp., Milford, MA).The ACQUITY UPLC Oligonucleotides BEH C18 column (50 mm × 2.1 mm, 1.7 μm) maintained at 60 °C temperature was used for the chromatographic separation of the analyte.A gradient program was employed with the mobile phase combining solvent A (15 mM triethylamine, 400 mM hexafluoroisopropanol in water) and solvent B (50% methanol, 50% solvent A, v/v) as follows: 25% B (0−0.For mass spectrometric detection, the electrospray source was operated in the negative resolution mode.The optimized source parameters were as follows: capillary voltage 2.7 kV, cone voltage 40 V, desolvation gas flow 600 L/h with the temperature 400 °C, nebulizer gas pressure 6.5 bar, and source temperature 120 °C.Mass spectra were over an m/z range of 500−2000.Mass spectrometer conditions were optimized by the direct infusion of the standard solution.The system was controlled by using MassLynx software (Version 4.1).The raw ESI mass spectra were deconvoluted by using the MaxEnt1 algorithm to a zero-charge state mass.

Figure 1 .
Figure 1.General outline; the experimental model for in vitro transcription studies using ATP analogues.(A) Series of ATP analogues used in current studies.(B) Schematic representation of the transcription in vitro experimental model.(C) Sequences of template, primers, and RNA products.

2 . 3 .
Substrate Preferences of T7 RNA Polymerase toward α-Thio-Modified ATP Derivatives in the Presence of ATP.In order to compare substrate preferences of T7 RNA polymerase toward α-thio-modified 2 and 4 derivatives, the in vitro transcription reaction was performed in the presence of unmodified ATP and S P diastereomers of α-thioβ,γ-hypo-ATP (4) or α-thio-ATP (2), respectively.

Figure 2 .
Figure 2. In vitro transcription using diastereomerically pure α-thioβ,γ-hypo-ATP (4) analogues as substrates for T7 RNA polymerase.ATP and its analogues were used at concentrations of 0.1, 0.5, 1, and 2 mM.(A) PAGE analysis of the transcription reaction mixture.(B) Determination of the reaction products by microfluidics bioanalysis.

Figure 5 .
Figure 5. Mass spectrometry analysis of T7 RNA polymerase substrate preferences toward ATP and α-thio-modified ATP analogues.The detection of PS-modified RNA as a product of in vitro transcription conducted in the presence of ATP and α-thio-modified ATP analogues: ATP with S P -4 (upper panel) or in the presence of S P -2 with ATP (lower panel).From the top, simulated mass spectra of unmodified and PS-modified products containing from 1 to 6 phosphorothioate modifications.The lowest graphs in each part (in the green part) present experimental results of the MS analysis of transcription reaction products.The results were obtained after deconvolution of the raw ESI mass spectra using the MaxEnt1 algorithm to a zero-charge state mass.

Figure 6 .
Figure 6.PAGE analysis of the in vitro transcription efficacy in the presence of S P and R P diastereomers of α-thio-β,γ-hypo-ATP (4) used at concentrations of 0.1, 0.5, 1, and 2 mM.

Figure 7 .
Figure 7. PAGE analysis of the in vitro transcription efficiency in the presence of hypodiphosphoric and pyrophosphoric acids with an increasing amount of ATP, lines 2−5 and 6−9: 0.1, 0.5, 1, and 2 mM ATP, respectively.

, 1 H
NMR and31 P NMR spectra, mass spectrometry and HPLC profiles of all synthesized compounds; FigureS22, mass spectrometry analysis of the [M-9H + ] 9− ion of the reaction products of the in vitro transcription conducted in the presence of ATP and α-thio-modified ATP analogues; FigureS23, PAGE analysis of the in vitro transcription efficiency in the presence of an increasing amount of pyrophosphoric acid; and Table S1, calculated and experimentally confirmed monoisotopic mass of RNA strands synthesized by the T7 RNA polymerase in the presence of ATP and α-thio-modified ATP analogues (PDF) Department of Bioorganic Chemistry, Centre of Molecular and Macromolecular Studies, Polish Academy of Sciences, 90-363 Lodz, Poland; orcid.org/0000-0002-3123-8949; Email: roza.pawlowska@cbmm.lodz.pl